eISSN: 1643-3750

Logo




Get your full text copy in PDF

Chronic alpha1-adrenergic blockade improves hypertension and renal injury in L-NAME and low-renin L-NAME-DOCA hypertensive rats

Rosemary Wangensteen, Francisco O’Valle, Raimundo G. Del Moral, Félix Vargas, Antonio Osuna

Med Sci Monit 2002; 8(9): BR378-384

ID: 13270


Summary
Background: The present study investigated the contribution of α1-adrenergic blockade to hypertension induced by long-term blockade of nitric oxide and chronic treatment with deoxycorticosterone
acetate (DOCA), which produced a low renin model of hypertension. We studied the effects of chronic administration of prazosin, an α1-receptor antagonist, on blood pressure (BP), renal injury, and other variables in Nω-nitro-L-arginine methyl ester (L-NAME) and LNAME+
DOCA hypertensive rats.
Material/Methods: The rats were divided into 6 groups: Control, DOCA, L-NAME, L-NAME+DOCA, L-NAME+ prazosin, and L-NAME+DOCA+prazosin. Tail systolic BP was measured twice a week. After a 6-week evolution, mean arterial pressure (MAP) was measured, along with selected metabolic, morphological and renal variables.
Results: The final MAP values were 105±1 for Control, 107±0.6 for DOCA, 153±3 for L-NAME, 175±2 for L-NAME+DOCA, 126±2 for L-NAME+prazosin and 127±5 for L-NAME+ DOCA+prazosin. Proteinuria and hyaline arteriopathy were prevented in L-NAME+prazosin
rats and markedly attenuated in the L-NAME+DOCA+prazosin group. Plasma urea and creatinine were significantly increased in the L-NAME+DOCA group, but not in the L-NAME+ DOCA+prazosin group as against controls. The DOCA and DOCA+L-NAME groups showed
relative renal and cardiac hypertrophy, which was not observed in the DOCA+L-NAME+prazosin group.
Conclusions: α1-adrenergic tone plays an important role in the increased BP and renal injury of L-NAME hypertension. Our results also indicate that when PRA is suppressed by DOCA in L-NAME
hypertension, the increased BP and renal injury are largely dependent on the α1-adrenergic tone.

This paper has been published under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) allowing to download articles and share them with others as long as they credit the authors and the publisher, but without permission to change them in any way or use them commercially.
I agree